NFXBio: Why C2i is the World’s First Platform for Cancer Intelligence

In this episode, James Currier and Omri Amirav-Drory delve into synthetic biology and tech bio, introducing guest Asaf Zviran, CEO of C2I. They discuss the impact of tech bio on industries, strategies for hiring and fundraising in a virtual world, and the balance between science and business in startups. They also explore the future of cancer treatment and provide valuable advice for startup founders.

The team at C2i Genomics is combining cutting-edge genomics and sophisticated AI to provide the world’s first whole-genome cancer intelligence platform, transforming the way cancer is monitored and treated.

C2i uses a blood test that can detect and quantify tiny amounts of residual cancer to better monitor cancer treatment, progression, and recurrence. NFX was an early stage investor in C2i due to their long-term vision and world-changing technology.

Listen to NFX Partner Omri Amirav-Drory talk with Asaf Zviran, Co-founder & CEO of C2i Genomics, about the future of their company, their latest technological breakthroughs, and where the industry is headed in the near future.

Asaf and Omri's conversation begins at 11:15

Visit C2i to learn more - https://c2i-genomics.com/

(0:00) Introduction and Discussion on Synthetic Biology and Tech Bio (1:24) Introduction to Omri Amirav-Drory and NFX Bio (3:03) Impact of Tech Bio on Various Industries and Future Developments (6:28) Introduction to Pete and Liquid Biopsy for Cancer Monitoring (11:18) NFX Bio Investment Thesis and Conversation with Asaf Zviran, CEO and Founder of C2I (25:23) Asaf Zviran on Managing a Diverse Team and Overcoming Challenges (29:43) Hiring, Recruiting, and Fundraising Strategies in a Virtual World (31:20) Balancing Science and Business in a Startup and Transition from Academia to Industry (38:07) End of Part 1 and Transition to Part 2: Series B Funding and Scaling Up (41:46) Overcoming Challenges in Bio Startups and Future of Cancer Treatment (44:51) Advices for Startup Founders and Quick-fire Round (48:25) Closing Remarks and End of Episode